GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pfizer Inc (WBO:PFE) » Definitions » Piotroski F-Score

Pfizer (WBO:PFE) Piotroski F-Score : 5 (As of Dec. 14, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Pfizer Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Pfizer has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Pfizer's Piotroski F-Score or its related term are showing as below:

WBO:PFE' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 8
Current: 5

During the past 13 years, the highest Piotroski F-Score of Pfizer was 8. The lowest was 3. And the median was 6.


Pfizer Piotroski F-Score Historical Data

The historical data trend for Pfizer's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pfizer Piotroski F-Score Chart

Pfizer Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 5.00 7.00 7.00 4.00

Pfizer Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 4.00 3.00 4.00 5.00

Competitive Comparison of Pfizer's Piotroski F-Score

For the Drug Manufacturers - General subindustry, Pfizer's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pfizer's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pfizer's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Pfizer's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Net Income was -3089.373 + 2865.8 + 38.089 + 4022.965 = €3,837 Mil.
Cash Flow from Operations was 4805.08 + 1002.8 + -1654.549 + 6049.314 = €10,203 Mil.
Revenue was 12390.504 + 13687.76 + 12339.907 + 15948.601 = €54,367 Mil.
Gross Profit was 5455.233 + 10579.08 + 9274.207 + 11206.638 = €36,515 Mil.
Average Total Assets from the begining of this year (Sep23)
to the end of this year (Sep24) was
(201474.677 + 207701.417 + 203407.4 + 200843.297 + 197747.876) / 5 = €202234.9334 Mil.
Total Assets at the begining of this year (Sep23) was €201,475 Mil.
Long-Term Debt & Capital Lease Obligation was €51,283 Mil.
Total Current Assets was €38,944 Mil.
Total Current Liabilities was €38,933 Mil.
Net Income was 4714.336 + 5177.162 + 2147.821 + -2231.934 = €9,807 Mil.

Revenue was 22929.76 + 17264.99 + 12004.538 + 12642.004 = €64,841 Mil.
Gross Profit was 13822.048 + 12701.466 + 9016.787 + 3956.951 = €39,497 Mil.
Average Total Assets from the begining of last year (Sep22)
to the end of last year (Sep23) was
(197303.5 + 186161.52 + 182706.278 + 203215.064 + 201474.677) / 5 = €194172.2078 Mil.
Total Assets at the begining of last year (Sep22) was €197,304 Mil.
Long-Term Debt & Capital Lease Obligation was €57,202 Mil.
Total Current Assets was €69,349 Mil.
Total Current Liabilities was €29,174 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Pfizer's current Net Income (TTM) was 3,837. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Pfizer's current Cash Flow from Operations (TTM) was 10,203. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep23)
=3837.481/201474.677
=0.01904696

ROA (Last Year)=Net Income/Total Assets (Sep22)
=9807.385/197303.5
=0.0497071

Pfizer's return on assets of this year was 0.01904696. Pfizer's return on assets of last year was 0.0497071. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Pfizer's current Net Income (TTM) was 3,837. Pfizer's current Cash Flow from Operations (TTM) was 10,203. ==> 10,203 > 3,837 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep23 to Sep24
=51283.118/202234.9334
=0.2535819

Gearing (Last Year: Sep23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep22 to Sep23
=57201.976/194172.2078
=0.29459404

Pfizer's gearing of this year was 0.2535819. Pfizer's gearing of last year was 0.29459404. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep24)=Total Current Assets/Total Current Liabilities
=38943.923/38933.111
=1.00027771

Current Ratio (Last Year: Sep23)=Total Current Assets/Total Current Liabilities
=69349.244/29174.432
=2.3770555

Pfizer's current ratio of this year was 1.00027771. Pfizer's current ratio of last year was 2.3770555. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Pfizer's number of shares in issue this year was 5705. Pfizer's number of shares in issue last year was 5646. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=36515.158/54366.772
=0.67164477

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=39497.252/64841.292
=0.60913734

Pfizer's gross margin of this year was 0.67164477. Pfizer's gross margin of last year was 0.60913734. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep23)
=54366.772/201474.677
=0.26984419

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep22)
=64841.292/197303.5
=0.32863731

Pfizer's asset turnover of this year was 0.26984419. Pfizer's asset turnover of last year was 0.32863731. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+0+0+1+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Pfizer has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Pfizer  (WBO:PFE) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Pfizer Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Pfizer's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Pfizer Business Description

Address
66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.